leadf
logo-loader
RNS
viewReNeuron Group PLC

ReNeuron Group plc - Total Voting Rights

RNS Number : 8403U
ReNeuron Group plc
03 August 2020
 

 

 

3 August 2020

AIM: RENE

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Total Voting Rights

 

At 31 July 2020, the Company had 31,848,204 ordinary shares in issue, each carrying one voting right. This follows the issue of 14,434 new shares arising from the exercise of options by staff, such shares having been admitted under the Company's existing block listing arrangement.

 

As the Company holds no ordinary shares in treasury, the figure of 31,848,204 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

  

ENDS

 

ENQUIRIES:

 

ReNeuron

+44 (0)20 3819 8400

Olav Hellebø, Chief Executive Officer


Michael Hunt, Chief Financial Officer

 

 


Buchanan (Media/Investor relations)

+44 (0) 20 7466 5000

Mark Court, Tilly Abraham

 

 


Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

+44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison

(NOMAD and Joint Broker)

 

 


N+1 Singer (Joint Broker)

+44 (0) 20 7496 3000

Aubrey Powell, James Moat, Tom Salvesen


 

 



About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. 

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain.  The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRDZGFNVMZGGZM

Quick facts: ReNeuron Group PLC

Price: 87.5

Market: LSE
Market Cap: £27.89 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18